VIPC’s Robert Stolle Announces Plans to Step Down From His Role as President and CEO

As CEO, Bob Stolle led Virginia’s consolidation of several innovation and entrepreneurship programs into the newly established VIPC. This consolidation expanded and coordinated programs that provide support for Virginia’s entrepreneurs, tech startups, research commercialization, regional ecosystems, and new industry sectors such as Advanced Air Mobility and Smart Communities.

“Having the privilege of leading VIPC over the last three years has been the most rewarding experience of my professional career” Stolle said. “VIPC has a staff of exceptionally talented and experienced professionals. I’m very proud of where we are as a team, but I believe this is a good time to pass the baton to the next generation of leadership for innovation in Virginia”.

“The Commonwealth has benefited greatly and will continue to benefit for years to come from Bob’s many years of investing his considerable talents, time, and exemplary service,” said Caren Merrick, Secretary of Commerce and Trade and Vice Chair of VIPC.

“Under Bob’s leadership, VIPC has forged a series of integrated programs to help entrepreneurs bring their technologies to commercialization, whether the technology originates in one of Virginia’s academic institutions or in the private sector. As an entrepreneur myself, I know that these programs make a real difference in the success of our emerging and growing tech enterprise,” said Barbara D. Boyan, PhD, Chair of the VIPC Board of Directors and Executive Director of the Institute for Engineering and Medicine at Virginia Commonwealth University.

Joseph Benevento, Virginia Deputy Secretary of Commerce & Trade, will assume the role of Interim CEO beginning in September, while the VIPC Board recruits a permanent CEO. Bob Stolle will stay on in an advisory role to assist in the transition until at least the end of October.

“I’m very grateful to the VIPC Board of Directors and to the Youngkin Administration for their trust, support, and for the opportunity to serve the Commonwealth of Virginia” Stolle said.

Learn more here.

Recent News


Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential


KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury


Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst